JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Negative 90.9%

Neg 90.9% Neu 0% Pos 0%

JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $12 to $9.